Alexey V Danilov

29PUBLICATIONS
164CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumoursMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|May 18, 2026
Cyclin-Dependent Kinase 5 Contributes to Bruton's Tyrosine Kinase Inhibitor Resistance via the IRE1α/XBP1 Axis in Mantle Cell Lymphoma.

|Apr 28, 2026
Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma.

|Apr 25, 2026
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

|Apr 09, 2026
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025.

Alexey V Danilov, Catherine C Coombs, Tycel Phillips

|Mar 24, 2026
Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study.

Matthew Hamby, Brian L Egleston, Zachary A K Frosch

|Feb 19, 2026
Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma.

Daniel Filip, Katerina Litzmanova, Androniki Michaelou

Pageof 5

Frequent Collaborators

6 joint publications

Geoffrey Shouse

5 joint publications

Lili Wang

4 joint publications

Stefan K Barta

4 joint publications

Yucai Wang